Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC)
| Autor: | Mahadi Ali Baig, Min Ren, Mayer Fishman, Thomas E. Hutson, Corina E. Dutcus |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty animal structures Everolimus business.industry fungi Phases of clinical research medicine.disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Renal cell carcinoma 030220 oncology & carcinogenesis Internal medicine embryonic structures medicine Overall survival Clinical endpoint 030212 general & internal medicine business Lenvatinib medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 34:4553-4553 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 4553Background: In the randomized phase 2 study of LEN, EVE, and LEN+EVE in mRCC, LEN+EVE significantly improved the primary endpoint median progression-free survival (PFS) vs EVE (14.6 vs 5.5 mont... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|